Aaron Weitzman

2.4k citations
39 papers · 1.3k · 1 hit paper · h-index 15

Impact in

  • Hematology top 1%
    • Chronic Myeloid Leukemia Treatments
    • Acute Myeloid Leukemia Research
  • Genetics top 2%
    • Chronic Lymphocytic Leukemia Research

Papers in

Co-authors
Francis J. Giles (7 shared papers)Philipp le Coutre (9 shared papers)Hagop M. Kantarjian (8 shared papers)Yaping Shou (4 shared papers)Kapil N. Bhalla (6 shared papers)Andreas Hochhaus (8 shared papers)Md Ariful Haque (5 shared papers)Norbert Gattermann (5 shared papers)
Journals
Journal of Clinical Oncology (15 papers)Blood (7 papers)Cancer Research (2 papers)Annals of Oncology (2 papers)The Breast (1 paper)
Partner nations
United StatesGermanyUnited Kingdom

In The Last Decade

Aaron Weitzman

38 papers receiving 1.2k citations

Aaron Weitzman's Hit Papers

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance 2007 · 566 citations
5660+6+12Years since publication100200300400500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2007 Blood

Peers

Aaron Weitzman
Comparison fields: 5 of 72
  • Hematology 682
  • Genetics 468
  • Rheumatology 343
  • Oncology 263
  • Pulmonary and Respiratory Medicine 229
Replace Steven Knapper with:
Steven Knapper United Kingdom
Mark W. Drummond United Kingdom
P. Berthaud France
Chao Zhu China
Marek Hus Poland
Joanne Lager United States
Juan Luis Steegmann Spain
Kevin Yee United States
M.S. Gordon United States
Sharianne G. Louie United States
Aaron Weitzman relative to Steven Knapper United Kingdom Steven Knapper's profile →
Citations per field
00.5×2×3×3.8×
Steven Knapper · 1×
Citations per year

Countries citing papers authored by Aaron Weitzman

Since Specialization
Citations

This map shows the geographic impact of Aaron Weitzman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aaron Weitzman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aaron Weitzman more than expected).

Fields of papers citing papers by Aaron Weitzman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aaron Weitzman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aaron Weitzman. The network helps show where Aaron Weitzman may publish in the future.

Co-authors

The 25 scholars most cited alongside Aaron Weitzman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Aaron Weitzman Line = papers co-authored together Aaron Weitzman links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 39 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Blood ·Hagop M. Kantarjian, Francis J. Giles, Norbert Gattermann, Kapil N. Bhalla, Giuliana Alimena, Francesca Palandri, Gert J. Ossenkoppele, Franck-Emmanuel Nicolini, Stephen G. O’Brien, Mark R. Litzow, Ravi Bhatia, Francisco Cervantes, Md Ariful Haque, Yaping Shou, Debra Resta, Aaron Weitzman, Andreas Hochhaus, Philipp le Coutre
Hit paper breakdown →		2007566
2
UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia
Leukemia ·Jonathan B. Singer, Yaping Shou, Francis J. Giles, H Kantarjian, Yanzhi Hsu, Anna Robeva, P. Rae, Aaron Weitzman, Joanne M. Meyer, Margaret Dugan, Oliver G. Ottmann
200798
3
Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.
PubMed ·Daniel P. Petrylak, Robert B. MacArthur, Jacqueline M. O’Connor, Gary Shelton, Aaron Weitzman, Timothy Judge, C England-Owen, Nancy Zuech, Charles Pfaff, Jeffrey H. Newhouse, Emilia Bagiella, D Hetjan, Ihor Sawczuk, Mitchell C. Benson, Carl A. Olsson
199980
4
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma
British Journal of Cancer ·Adil Daud, Harriet M. Kluger, Razelle Kurzrock, Frauke Schimmöller, Aaron Weitzman, Thomas A. Samuel, Ali H. Moussa, Michael S. Gordon, Geoffrey I. Shapiro
201753
5
DEXAMETHASONE DOES NOT SIGNIFICANTLY CONTRIBUTE TO THE RESPONSE RATE OF DOCETAXEL AND ESTRAMUSTINE IN ANDROGEN INDEPENDENT PROSTATE CANCER
The Journal of Urology ·Aaron Weitzman, Gary Shelton, Nancy Zuech, Cindy E. Owen, Timothy Judge, Mitchell C. Benson, Ihor S. Sawczuk, Aaron E. Katz, Carl A. Olsson, Emilia Bagiella, Charles Pfaff, Jeffrey H. Newhouse, Daniel P. Petrylak
200052
6
Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial
JAMA Oncology ·Amylou C. Dueck, Howard I. Scher, Antonia V. Bennett, Gina L. Mazza, Gita Thanarajasingam, Gisela Schwab, Aaron Weitzman, Lauren J. Rogak, Ethan Basch
201945
7
Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).
Journal of Clinical Oncology ·Matthew R. Smith, Johann S. de Bono, Cora N. Sternberg, Sylvestre Le Moulec, Stéphane Oudard, Ugo De Giorgi, Michael Krainer, Andries M. Bergman, Wolfgang Hoelzer, Ronald de Wit, Martin Boegemann, Fred Saad, Giorgio Cruciani, Antoine Thiery Vuillemin, Susan Feyerabend, Kurt Miller, David A. Ramies, Colin Hessel, Aaron Weitzman, Karim Fizazi
201534
8
Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort
European Urology ·Ethan Basch, Karen A. Autio, Matthew R. Smith, Antonia V. Bennett, Aaron Weitzman, Christian Scheffold, Christopher J. Sweeney, Dana E. Rathkopf, David C. Smith, Daniel J. George, Celestia S. Higano, Andrea Harzstark, Oliver Sartor, Michael S. Gordon, Nicholas J. Vogelzang, Johann S. de Bono, Naomi B. Haas, Paul G. Corn, Frauke Schimmöller, Howard I. Scher
201433
9
Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).
Journal of Clinical Oncology ·Ethan Basch, Mark C. Scholz, Johann S. de Bono, Nicholas J. Vogelzang, Paul L. de Souza, Gavin Marx, Ulka N. Vaishampayan, Saby George, James K. Schwarz, Emmanuel S. Antonarakis, Joe M. O’Sullivan, Arash Rezazadeh Kalebasty, Kim N., Robert Dreicer, Thomas E. Hutson, Milan Mangeshkar, Jaymes Holland, Aaron Weitzman, Howard I. Scher
201531
10
Phase I and Pharmacokinetic Study of LY293111, an Orally Bioavailable LTB4 Receptor Antagonist, in Patients With Advanced Solid Tumors
Journal of Clinical Oncology ·Gary K. Schwartz, Aaron Weitzman, Eileen M. O’Reilly, Les Brail, Dinesh P. de Alwis, Ann Cleverly, Barbara Barile-Thiem, Vincent Vinciguerra, Daniel R. Budman
200527
11
A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours
Investigational New Drugs ·Tara Baetz, Elizabeth A. Eisenhauer, Lillian L. Siu, Martha MacLean, Karen Doppler, Wendy Walsh, B. Fisher, Azhar Khan, Dinesh P. de Alwis, Aaron Weitzman, Leslie H. Brail, Malcolm Moore
200626
12
A Phase II Study of Nilotinib A Novel Tyrosine Kinase Inhibitor Administered to Imatinib-Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Accelerated Phase (AP).
Blood ·Hagop M. Kantarjian, Norbert Gattermann, Andreas Hochhaus, Richard A. Larson, Teresa Rafferty, Aaron Weitzman, Md Ariful Haque, Francis J. Giles, S G O'Brien, Philipp le Coutre
200619
13
A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Imatinib Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Blast Crisis (BC) or Relapsed/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL).
Blood ·Oliver G. Ottmann, Hagop M. Kantarjian, Richard A. Larson, Philipp le Courte, Michele Baccarani, Teresa Rafferty, Aaron Weitzman, Francis J. Giles
200618
14
A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Patients with Imatinib Resistant or Intolerant Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP), Accelerated Phase (AP) or Blast Crisis (BC) Who Have Also Failed Dasatinib Therapy.
Blood ·Francis J. Giles, Philipp le Coutre, Kapil N. Bhalla, Gianantonio Rosti, G.J. Ossenkopplele, Giuliana Alimena, Aaron Weitzman, Teresa Rafferty, Ming Zheng, Hagop M. Kantarjian
200618
15
Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer
The Breast ·Amy Tiersten, Jennifer Y. Wo, Caron A. Jacobson, Aaron Weitzman, Tamara B. Horwich, Charles Hesdorffer, David G. Savage, Andrea B. Troxel
200418
16
A phase II study of nilotinib administered to imatinib resistant and intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP)
Journal of Clinical Oncology ·G. Rosti, Philipp le Coutre, Kapil N. Bhalla, F. Giles, G. J. Ossenkoppele, Andreas Hochhaus, Norbert Gattermann, Md Ariful Haque, Aaron Weitzman, Michele Baccarani, Hagop M. Kantarjian
200714
17
First-in-human phase I study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager in patients with metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology ·Johanna C. Bendell, Lawrence Fong, Mark N. Stein, Tomasz M. Beer, Ashley E. Ross, Xīn Gào, Aaron Weitzman, Richard J. Austin, Vaishnavi Ganti, Che‐Leung Law, Bryan D. Lemon, Holger Wesche, Johann S. de Bono
202013
18
The relation of plasma total homocysteine levels to prevalent cardiovascular disease in older patients with ischemic stroke
Aging Clinical and Experimental Research ·Abraham Adunsky, Aaron Weitzman, Y. Fleissig, L. Levenkrohn, M. Arad, Ram Doolman, S Gavendo, Ben‐Ami Sela
200013
19
A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib
Journal of Clinical Oncology ·Francis J. Giles, Philipp le Coutre, Kapil N. Bhalla, G. Rosti, G. J. Ossenkoppele, G. Alimena, Aaron Weitzman, Ming Zheng, Hagop M. Kantarjian
200713
20
Activity of cabozantinib in metastatic uveal melanoma: Updated results from a phase II randomized discontinuation trial (RDT).
Journal of Clinical Oncology ·Adil Daud, Harriet M. Kluger, Gerald M. Edelman, Michael S. Gordon, Frauke Schimmöller, Aaron Weitzman, Thomas A. Samuel, Ali H. Moussa, Keith T. Flaherty, Geoffrey I. Shapiro
201312

About Aaron Weitzman

Aaron Weitzman is a scholar working on Genetics, Pulmonary and Respiratory Medicine, Oncology, Hematology and Rheumatology, having authored 39 papers that have together received 1.3k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (12 papers), Chronic Lymphocytic Leukemia Research (12 papers), Eosinophilic Disorders and Syndromes (10 papers), Prostate Cancer Treatment and Research (9 papers), Cancer Treatment and Pharmacology (8 papers), Advanced Breast Cancer Therapies (4 papers), Acute Lymphoblastic Leukemia research (3 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). The work is most often cited by research in Hematology (682 citations), Genetics (468 citations), Rheumatology (343 citations), Oncology (263 citations) and Pulmonary and Respiratory Medicine (229 citations). Aaron Weitzman has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Francis J. Giles, Philipp le Coutre, Hagop M. Kantarjian, Yaping Shou, Kapil N. Bhalla, Andreas Hochhaus, Md Ariful Haque, Norbert Gattermann, Giuliana Alimena and Francesca Palandri. Their work appears in journals such as Journal of Clinical Oncology, Blood, Cancer Research, Annals of Oncology and The Breast.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steven KnapperBreakdown of academic impact, for papers by Mark W. DrummondBreakdown of academic impact, for papers by P. BerthaudBreakdown of academic impact, for papers by Chao ZhuBreakdown of academic impact, for papers by Marek HusBreakdown of academic impact, for papers by Joanne LagerBreakdown of academic impact, for papers by Juan Luis SteegmannBreakdown of academic impact, for papers by Kevin YeeBreakdown of academic impact, for papers by M.S. GordonBreakdown of academic impact, for papers by Sharianne G. Louie